We detected that your JavaScript seem to be disabled.

You must have JavaScript enabled in your browser to utilize the functionality of this website.

Home /
News & Events - News

Recent News

Monday, December 5, 2011
Roche, ChanTest collaborate for preclinical cardiac safety testing of drug compounds using iCell Cardiomyocytes and xCELLigence RTCA Cardio Instrument

Monday, Nov. 21, 2011
ChanRx Secures Series A Funding

Thursday, June 9, 2011
ChanTest Signs Research Collaboration Agreement With the FDA
Goal: To Improve Preclinical Cardiac Risk Assessments

Wednesday, April 6, 2011
ChanTest Corporation First To Offer New High Throughput Electrophysiology Platform Validated for Both VGICs and LGICs

Thursday, March 24, 2011
ChanTest Corporation and Molecular Devices, Inc. Sign Cell Line Distribution Agreement

Thursday, September 9, 2010
D. Thomas Oakley Named President and CEO of Chantest Corporation

Thursday, July 15, 2010
Emir Duzic to Head GPCR Assay Services for ChanTest Corporation

Monday, June 21, 2010
Drug Safety Executive Council Presents: Improved Strategies for Pre-clinical Cardiac Testing

Thursday, February 04, 2010
ChanTest CEO to Speak on New Pre-Clinical Assays for Predicting Cardiotoxicity at Society of Toxicology Annual Meeting - ChanTest to Host Webinar March 23

Thursday, February 04, 2010
ChanTest To Hold Free Webinar on Stem Cell-Derived Human Cardiomyocyte Assays in Cardiac Risk Evaluation

Sunday, November 11, 2009
Dr. John Mills and Joseph Gentile Join Board of Directors of ChanTest Corporation

Wednesday, May 06, 2009
ChanTest Awarded $4.8 Million Through the Ohio Third Frontier Research and Commercialization Program

Tuesday, March 10, 2009
ChanTest to Highlight Expanded Ion Channel and GPCR Services and Cell Lines at ToxExpo, Booth 3056

Thursday, February 26, 2009
ChanTest Acquires Applied Cell Sciences